tradingkey.logo

Celcuity dips as H.C. Wainwright downgrades to 'neutral'

ReutersNov 17, 2025 7:10 PM

H.C. Wainwright downgrades cancer diagnostics firm Celcuity CELC.O to "neutral" from "buy"; raises PT to $94 from $77

Brokerage sees the pre-revenue company with a single asset, gedatolisib, and a $4.3 billion valuation as a stock priced for perfection with more downside risk than upside

CELC's stock price has appreciated about 608% YTD

H.C. Wainwright notes that the FDA has accepted an NDA for gedatolisib in wild-type PIK3CA breast cancer, but risks remain around potential delays, strong competition from large pharma, and weaker-than-expected pricing or adoption

Shares of Celcuity CELC.O down about 2.96% to $89.94 in afternoon trading

Eight of nine brokerages rate stock "buy" or higher, one "hold"; median PT is $96.50 — data compiled by LSEG

Including session's moves, CELC stock has risen ~587.1% YTD

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Tradingkey

Related Articles

Tradingkey
KeyAI